Literature DB >> 10207164

Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria.

R L Lindberg1, R Martini, M Baumgartner, B Erne, J Borg, J Zielasek, K Ricker, A Steck, K V Toyka, U A Meyer.   

Abstract

Acute porphyrias are inherited disorders caused by partial deficiency of specific heme biosynthesis enzymes. Clinically, porphyrias are manifested by a neuropsychiatric syndrome that includes peripheral neuropathy. Although much is known about the porphyrias' enzyme defects and their biochemical consequences, the cause of the neurological manifestations remains unresolved. We have studied porphyric neuropathy in mice with a partial deficiency of porphobilinogen deaminase (PBGD). PBGD-deficient mice (PBGD-/-) imitate acute porphyria through massive induction of hepatic delta-aminolevulinic acid synthase by drugs such as phenobarbital. Here we show that PBGD-/- mice develop impairment of motor coordination and muscle weakness. Histologically femoral nerves of PBGD-/- mice exhibit a marked decrease in large-caliber (>8 microm) axons and ultrastructural changes consistent with primary motor axon degeneration, secondary Schwann cell reactions, and axonal regeneration. These findings resemble those found in studies of affected nerves of patients with acute porphyria and thus provide strong evidence that PBGD deficiency causes degeneration of motor axons without signs of primary demyelination, thereby resolving a long-standing controversy. Interestingly, the neuropathy in PBGD-/- mice developed chronically and progressively and in the presence of normal or only slightly (twofold) increased plasma and urinary levels of the putative neurotoxic heme precursor delta-aminolevulinic acid. These data suggest that heme deficiency and consequent dysfunction of hemeproteins can cause porphyric neuropathy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10207164      PMCID: PMC408280          DOI: 10.1172/JCI5986

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  [Peripheral nerve lesions in acute intermittent porphyria].

Authors:  Y Wakayama; T Muroga; R Hibino; T Matsui; M Utsumi
Journal:  Rinsho Shinkeigaku       Date:  1975-06

2.  ON THE NATURE OF THE PERIPHERAL NERVE LESIONS ASSOCIATED WITH ACUTE INTERMITTENT PORPHYRIA.

Authors:  J B CAVANAGH; R S MELLICK
Journal:  J Neurol Neurosurg Psychiatry       Date:  1965-08       Impact factor: 10.154

3.  Delta-aminolaevulinic acid is a potent agonist for GABA autoreceptors.

Authors:  M J Brennan; R C Cantrill
Journal:  Nature       Date:  1979-08-09       Impact factor: 49.962

4.  Neuropathy in latent hereditary hepatic porphyria.

Authors:  P Mustajoki; A M Seppălăinen
Journal:  Br Med J       Date:  1975-05-10

5.  Prophyrin precursors in blood, urine and cerebrospinal fluid in acute porphyria.

Authors:  V A Percy; B C Shanley
Journal:  S Afr Med J       Date:  1977-07-30

Review 6.  Acute intermittent porphyria. A clinical and biochemical study of 46 patients.

Authors:  J A Stein; D P Tschudy
Journal:  Medicine (Baltimore)       Date:  1970-01       Impact factor: 1.889

7.  Electrodiagnostic findings in acute porphyric neuropathy.

Authors:  J W Albers; W C Robertson; J R Daube
Journal:  Muscle Nerve       Date:  1978 Jul-Aug       Impact factor: 3.217

8.  Heme biosynthesis in intermittent acute prophyria: decreased hepatic conversion of porphobilinogen to porphyrins and increased delta aminolevulinic acid synthetase activity.

Authors:  L J Strand; B F Felsher; A G Redeker; H S Marver
Journal:  Proc Natl Acad Sci U S A       Date:  1970-11       Impact factor: 11.205

9.  Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intravenous infusions of hematin.

Authors:  H L Bonkowsky; D P Tschudy; A Collins; J Doherty; I Bossenmaier; R Cardinal; C J Watson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-11       Impact factor: 11.205

10.  Electromyogram and nerve conduction in patients with acute intermittent porphyria.

Authors:  K A Flügel; K F Druschky
Journal:  J Neurol       Date:  1977-03-21       Impact factor: 4.849

View more
  28 in total

1.  Immune deficiency in mouse models for inherited peripheral neuropathies leads to improved myelin maintenance.

Authors:  C D Schmid; M Stienekemeier; S Oehen; F Bootz; J Zielasek; R Gold; K V Toyka; M Schachner; R Martini
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

2.  [Acute intermittent porphyria. A clinical chameleon: case study of a 40-year-old female patient].

Authors:  M Zimmermann; C Bonaccurso; C Valerius; G F Hamann
Journal:  Nervenarzt       Date:  2006-12       Impact factor: 1.214

3.  Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice.

Authors:  Carmen Unzu; Ana Sampedro; Itsaso Mauleón; Manuel Alegre; Stuart G Beattie; Rafael Enríquez de Salamanca; Jolanda Snapper; Jaap Twisk; Harald Petry; Gloria González-Aseguinolaza; Julio Artieda; María Sol Rodríguez-Pena; Jesús Prieto; Antonio Fontanellas
Journal:  Mol Ther       Date:  2010-09-28       Impact factor: 11.454

4.  The acute porphyrias: a diagnostic and therapeutic challenge in internal and emergency medicine.

Authors:  Paolo Ventura; Maria Domenica Cappellini; Emilio Rocchi
Journal:  Intern Emerg Med       Date:  2009-05-29       Impact factor: 3.397

Review 5.  Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies.

Authors:  Makiko Yasuda; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2019-01-18       Impact factor: 4.797

6.  The heme precursor delta-aminolevulinate blocks peripheral myelin formation.

Authors:  Natalia Felitsyn; Colin McLeod; Albert L Shroads; Peter W Stacpoole; Lucia Notterpek
Journal:  J Neurochem       Date:  2008-07-04       Impact factor: 5.372

7.  Distinct roles for laminin globular domains in laminin alpha1 chain mediated rescue of murine laminin alpha2 chain deficiency.

Authors:  Kinga I Gawlik; Mikael Akerlund; Virginie Carmignac; Harri Elamaa; Madeleine Durbeej
Journal:  PLoS One       Date:  2010-07-19       Impact factor: 3.240

8.  The dichloroacetate dilemma: environmental hazard versus therapeutic goldmine--both or neither?

Authors:  Peter W Stacpoole
Journal:  Environ Health Perspect       Date:  2010-10-04       Impact factor: 9.031

Review 9.  Role and relevance of PEPT2 in drug disposition, dynamics, and toxicity.

Authors:  Mohamed A Kamal; Richard F Keep; David E Smith
Journal:  Drug Metab Pharmacokinet       Date:  2008       Impact factor: 3.614

10.  In vivo electrophysiological measurements on mouse sciatic nerves.

Authors:  Alexander Schulz; Christian Walther; Helen Morrison; Reinhard Bauer
Journal:  J Vis Exp       Date:  2014-04-13       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.